News AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 10:05:16 06/02/2026 pm IST			5-day change	1st Jan Change
14,104.00 ^GBX	+0.89%		+3.71%	+2.28%

06/02	Diary - UK corporate earnings week ahead	RE
06/02	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE

06/02	Diary - UK corporate earnings week ahead	RE
06/02	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
06/02	ASTRAZENECA : Deutsche Bank maintains a Sell rating	ZD
06/02	US President Launches TrumpRx.gov to Offer Branded Drugs at Discounted Prices	MT
06/02	Oddo BHF cuts Wizz Air and Ryanair	AN
06/02	Aim Immunotech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen®? (Rintatolimod) in Combination with Astrazeneca's Imfinzi®? for the Treatment of Pancreatic Cancer	CI
05/02	Intervacc AB Announces Chief Executive Officer Changes	CI
05/02	AIM ImmunoTech reports year-end positive phase 2 interim progress for Ampligen® (rintatolimod) plus AstraZeneca's Imfinzi® (durvalumab) in pancreatic cancer	RE
05/02	European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading	MT
04/02	Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial	CI
04/02	HBM Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2025	CI
03/02	Astrazeneca plc Provides Update on US Regulatory Review of Saphnelo Subcutaneous Administration in Systemic Lupus Erythematosus	CI
03/02	European Stocks Mostly Lower in Tuesday Trading; Spain to Ban Social Media for Children; Credit Suisse Linked to Potential Nazi-Era Accounts	MT
03/02	Walmart hits $1 trillion in market value for the first time	RE
03/02	Global markets live: SpaceX, Tesla, Boeing, PayPal, AstraZeneca…
03/02	Kyverna Therapeutics, Inc. Appoints Mayo Pujols as Chief Technology Officer, Effective February 9, 2026	CI
03/02	Brace for the Earnings Flood
03/02	FTSE 100 down as rally falters, gold rebounds	AN
03/02	DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy	BU
03/02	FTSE 100 retreats from record high as tech selloff offsets gains in miners	RE
03/02	AstraZeneca Expects FDA Decision on Updated Subcutaneous Saphnelo Application in H1 2026	MT
03/02	European Midday Briefing : Stocks Rise; Investors Await More U.S. Tech Earnings	DJ
03/02	AstraZeneca says FDA backs Datroway, seeks more assurance on Saphnelo	AN
03/02	AstraZeneca Says Breast Cancer Treatment Granted US FDA Priority Review	MT
03/02	Stockholm Bullets - Fasadgruppen Plummets on Major Rights Issue	FW

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

AstraZeneca CFO on M&A Strategy and Obesity Market

January 14, 2026 at 04:04 am IST

AstraZeneca benefits from oncology momentum but valuation limits upside

November 19, 2025 at 06:13 pm IST

AstraZeneca's CEO reportedly considers listing in the United States

July 02, 2025 at 01:09 pm IST